Nevro wins FDA approval for pivotal trial of high-frequency spinal cord simulation
Nevro Corp.
Pain management: Neuromodulation company Nevro closes $58 million round
Nevro Corp., an early stage company that makes a spinal cord stimulator for chronic pain, has raised $58 million to continue development of its flagship product and prepare for a possible U.S. launch.
The Menlo Park, Calif.-based company said the funding round was led by Johnson & Johnson Development Corp. (NYSE: JNJ), along with existing investors Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners.